JP2016065795A - 非特異的反応阻害剤、それを用いた免疫学的測定法 - Google Patents
非特異的反応阻害剤、それを用いた免疫学的測定法 Download PDFInfo
- Publication number
- JP2016065795A JP2016065795A JP2014194707A JP2014194707A JP2016065795A JP 2016065795 A JP2016065795 A JP 2016065795A JP 2014194707 A JP2014194707 A JP 2014194707A JP 2014194707 A JP2014194707 A JP 2014194707A JP 2016065795 A JP2016065795 A JP 2016065795A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- rheumatoid factor
- type
- monoclonal antibody
- mouse monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002683 reaction inhibitor Substances 0.000 title claims abstract description 12
- 206010029719 Nonspecific reaction Diseases 0.000 title abstract description 15
- 238000003018 immunoassay Methods 0.000 title abstract description 15
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000010324 immunological assay Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000012295 chemical reaction liquid Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 25
- 238000005259 measurement Methods 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 210000000628 antibody-producing cell Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000000984 immunochemical effect Effects 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 3
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- XEQLGWAGMYUVTR-UHFFFAOYSA-N O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 XEQLGWAGMYUVTR-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007807 chemical reaction inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(2)有効成分として抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)を含有する非特異的反応阻害剤。
(1)HBRで抑制できなかった異好性抗体による非特異反応を抑制できるものである。
(2)HBRよりも少量の添加で異好性抗体による非特異反応を抑制できるものである。
・石川英治ら編「酵素免疫測定法」(第2版)((株)医学書院、1982年12月15日発行)
・臨床病理 臨時増刊 特集第53号「臨床検査のためのイムノアッセイ−技術と応用」(臨床病理刊行会、1983年発行)
・「バイオテクノロジー事典」((株)シーエムシー、1986年10月9日発行)
・「Methods in ENZYMOLOGY Vol.70」
(Immunochemical techniques(Part A))
・「Methods in ENZYMOLOGY Vol.73」
(Immunochemical techniques(Part B))
・「Methods in ENZYMOLOGY Vol.74」
(Immunochemical techniques(Part C))
・「Methods in ENZYMOLOGY Vol.84」
(Immunochemical techniques(Part D:Selected Immunoassay))
・「Methods in ENZYMOLOGY Vol.92」
(Immunochemical techniques(Part E:Monoclonal Antibodies and General Immunoassay Methods))
抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)の調製
精製ヒトリウマチ因子−IgM型を、フロインド完全アジュバンドと共に、BALB/cマウスに2〜3週間おきに3回腹腔内に投与した。3回免疫後、10μgをマウスに静脈投与し、最終免疫を行った。最終免疫から3日後にマウスの脾臓を摘出し、この脾臓細胞とマウス骨髄腫細胞Sp2/0−Ag14(Sp2)とをケラーとミルシュタインの方法に従って細胞融合した。すなわち、脾臓細胞と骨髄腫を10:1で混合後、遠心分離して得たペレットに50%ポリエチレングリコール含有RPMI1640溶液1mlを徐々に加えて細胞を融合した。さらにこれにRPMI1640培地を加えて10mlとし、遠心分離して得たペレットを10%ウシ胎児血清(FCS)含有RPMI1640培地にSp2として3×104個/100μlとなるように懸濁させ、96ウェルマイクロタイタープレート10枚に各ウェル100μlずつ分注した。
検体希釈液に本発明の抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)を25μg/mLの濃度になるように添加し、コントロールとして市販の異好性阻止試薬HBRを同様に25μg/mLの濃度になるように添加し、試験に供した。
その結果、下記表1に示すように、非特異反応の抑制効果は検体によって異なるが、本発明の抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)を用いた場合、市販のHBRと比較して、リウマチ因子保有検体やHAMA保有検体による非特異反応を有意に抑制できることが明らかになった。
ラテックスインスリンキット「ヤマサ」を使用し、本発明の抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)(9D3および3A3)または市販のHBRとの性能を比較した。
すなわち、キットの第一試薬に本発明の抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)または市販のHBRを100μg/mLの濃度になるように添加したものを使用した。
その結果、下記表2に示すように、非特異反応の抑制効果は検体によって異なるが、本発明の抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)を用いた場合、市販のHBRと比較し、リウマチ因子保有検体やHAMA保有検体による非特異反応を有意に抑制できることが明らかになった。
Claims (2)
- 反応液中に抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)を共存させることを特徴とする免疫学的測定法。
- 有効成分として抗ヒトリウマチ因子(IgM型)マウスモノクローナル抗体(IgG型)を含有する非特異的反応阻害剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014194707A JP6005705B2 (ja) | 2014-09-25 | 2014-09-25 | 非特異的反応阻害剤、それを用いた免疫学的測定法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014194707A JP6005705B2 (ja) | 2014-09-25 | 2014-09-25 | 非特異的反応阻害剤、それを用いた免疫学的測定法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016065795A true JP2016065795A (ja) | 2016-04-28 |
JP6005705B2 JP6005705B2 (ja) | 2016-10-12 |
Family
ID=55804086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014194707A Active JP6005705B2 (ja) | 2014-09-25 | 2014-09-25 | 非特異的反応阻害剤、それを用いた免疫学的測定法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6005705B2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018203572A1 (ja) * | 2017-05-02 | 2018-11-08 | 田中貴金属工業株式会社 | 非特異反応抑制剤 |
JP2019140987A (ja) * | 2018-02-21 | 2019-08-29 | 田中貴金属工業株式会社 | モノクローナル抗体および非特異反応抑制剤 |
JP2019140988A (ja) * | 2018-02-21 | 2019-08-29 | 田中貴金属工業株式会社 | モノクローナル抗体および非特異反応抑制剤 |
CN111363671A (zh) * | 2020-02-26 | 2020-07-03 | 天津医科大学 | 一种肠道厌氧微生物培养瓶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0968531A (ja) * | 1995-08-31 | 1997-03-11 | Sanyo Chem Ind Ltd | 免疫測定法 |
JP2001502795A (ja) * | 1996-10-11 | 2001-02-27 | ガンマ バイオロジカルズ インコーポレイテッド | 血液型抗原および抗体の検出に有用な方法および装置 |
JP2011027751A (ja) * | 2008-09-05 | 2011-02-10 | Sekisui Medical Co Ltd | モノクローナル抗体及びこれを用いた免疫学的測定方法 |
-
2014
- 2014-09-25 JP JP2014194707A patent/JP6005705B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0968531A (ja) * | 1995-08-31 | 1997-03-11 | Sanyo Chem Ind Ltd | 免疫測定法 |
JP2001502795A (ja) * | 1996-10-11 | 2001-02-27 | ガンマ バイオロジカルズ インコーポレイテッド | 血液型抗原および抗体の検出に有用な方法および装置 |
JP2011027751A (ja) * | 2008-09-05 | 2011-02-10 | Sekisui Medical Co Ltd | モノクローナル抗体及びこれを用いた免疫学的測定方法 |
Non-Patent Citations (1)
Title |
---|
JPN6016034646; 村田 誠、外4名: '全自動化学発光免疫測定装置CL-JACK専用試薬 CL SP-D「ヤマサ」の基礎的検討' 医学と薬学 Vol.71,No.12, 201412, Page.2303-2308 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018203572A1 (ja) * | 2017-05-02 | 2018-11-08 | 田中貴金属工業株式会社 | 非特異反応抑制剤 |
JPWO2018203572A1 (ja) * | 2017-05-02 | 2020-03-12 | 田中貴金属工業株式会社 | 非特異反応抑制剤 |
JP7051824B2 (ja) | 2017-05-02 | 2022-04-11 | 田中貴金属工業株式会社 | 非特異反応抑制剤 |
JP2019140987A (ja) * | 2018-02-21 | 2019-08-29 | 田中貴金属工業株式会社 | モノクローナル抗体および非特異反応抑制剤 |
WO2019163922A1 (ja) * | 2018-02-21 | 2019-08-29 | 田中貴金属工業株式会社 | モノクローナル抗体および非特異反応抑制剤 |
JP2019140988A (ja) * | 2018-02-21 | 2019-08-29 | 田中貴金属工業株式会社 | モノクローナル抗体および非特異反応抑制剤 |
WO2019163923A1 (ja) * | 2018-02-21 | 2019-08-29 | 田中貴金属工業株式会社 | モノクローナル抗体および非特異反応抑制剤 |
US11912783B2 (en) | 2018-02-21 | 2024-02-27 | Tanaka Kikinzoku Kogyo K.K. | Monoclonal antibody against IgM and non-specific reaction inhibitor |
CN111363671A (zh) * | 2020-02-26 | 2020-07-03 | 天津医科大学 | 一种肠道厌氧微生物培养瓶及其制备方法 |
CN111363671B (zh) * | 2020-02-26 | 2023-07-21 | 天津医科大学 | 一种肠道厌氧微生物培养瓶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6005705B2 (ja) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4342566A (en) | Solid phase anti-C3 assay for detection of immune complexes | |
AU2016203292B2 (en) | Monoclonal antibody, and immunoassay using same | |
JP6324970B2 (ja) | 抗ウロプラキンii抗体システムおよび方法 | |
JP6005705B2 (ja) | 非特異的反応阻害剤、それを用いた免疫学的測定法 | |
Uotila et al. | Monoclonal antibodies to human alphafetoprotein | |
Abe et al. | Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies | |
WO2019009346A1 (ja) | 抗ヒトIgG4モノクローナル抗体、およびその抗体を利用したヒトIgG4測定試薬 | |
JP6660934B2 (ja) | 免疫学的測定方法及び該方法に用いられる測定試薬 | |
JPWO2016136863A1 (ja) | L−fabpの免疫学的測定方法及び該方法に用いられる測定試薬 | |
DK166503B1 (da) | Monoklonalt anti-humant igg-antistof og fremgangsmaade til fremstilling af dette antistof | |
WO2015046444A1 (ja) | 抗アルドステロン抗体 | |
WO2014147873A1 (ja) | Hmgb1の分解産物と特異的に結合する抗体、並びにhmgb1の分解産物の測定方法及び測定試薬 | |
JPWO2009044561A1 (ja) | 抗proNT/NMNモノクローナル抗体 | |
JPH11153599A (ja) | 免疫学的測定方法 | |
Pradhan et al. | Anti-C reactive protein antibodies in Indian patients with systemic lupus erythematosus | |
WO1992019755A1 (en) | MONOCLONAL ANTIBODY AGAINST HUMAN β2-GLYCOPROTEIN I AND USE THEREOF | |
WO2017187656A1 (ja) | 抗医薬品抗体の測定方法 | |
WO1991006005A1 (fr) | Procede de titrage de l'acide d-vanillylmandelique, et reactif et kit utilises | |
Rouan et al. | Specific, high affinity colchicine binding monoclonal antibodies: development and characterization of the antibodies | |
JPH0453263B2 (ja) | ||
US7087391B2 (en) | Antibody to hepatocyte growth factor activator inhibitor-1 and use thereof | |
JPH05215749A (ja) | ヒトインタ−ロイキン−8の免疫学的測定法 | |
JP2023097737A (ja) | 試料中のhmgb1の測定方法及び測定試薬、抗hmgb1抗体を固定化した担体の非特異的凝集の抑制方法並びに試料中のhmgb1測定時の試薬ブランクの上昇の抑制方法 | |
JPH02131574A (ja) | ミニクローン | |
JPH0795067B2 (ja) | 免疫複合体の測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160519 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160907 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6005705 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |